J&J and Contineum's oral M1 inhibitor fails second mid-stage depression trial

Contineum Therapeutics and Johnson & Johnson reported that their oral M1 receptor inhibitor, known as PIPE-307 or JNJ-5120, did not meet its primary endpoints in a Phase II study for major depressive disorder.

This marks the second mid-stage trial in the past year where the compound failed to demonstrate statistical significance, indicating ongoing challenges in advancing the candidate.

The outcome delays any potential progression toward later-stage testing and may affect the companies' strategies for developing M1-targeted therapies in psychiatry.